Ozanimod for Crohn's Disease
Study Summary
This trial is testing a new drug to see if it can help people with Crohn's Disease.
Eligibility Criteria
Inclusion Criteria
You will be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2017 Phase 3 trial • 1320 Patients • NCT02047734Awards & Highlights
Trial Design
Find a site
Who is running the clinical trial?
Media Library
Frequently Asked Questions
Are there any safety concerns associated with Ozanimod?
"Ozanimod has some efficacy data from previous trials, and multiple rounds of safety testing have been completed, so it received a score of 3."
Are there any other similar trials to this one that have been conducted in the past?
"There have been 11 ongoing studies for Ozanimod in 52 countries and 287 cities since 2015. The first study, sponsored by Celgene, was completed in Phase 3 drug approval stage with 2350 participants."
In how many different geographical areas is this trial taking place?
"This clinical trial is presently enrolling patients at 77 sites. The locations are located in San Francisco, Bristol and Decatur as well as 77 other locations. It is important to select the site closest you so that you can minimize travel demands if you enroll."
To what demographics does this research pertain?
"Ileocolitis patients, between the ages of 18-75, who meet the following medical criteria are encouraged to apply: Must not have ulcerative colitis, an inadequate response or loss of response to corticosteroids, immunomodulators, and/or biologic therapy."
What is the research history of Ozanimod?
"Ozanimod was first studied in the year 2015 at Local Institution - 554. Out of the 18302 completed trials, 11 are ongoing with many taking place in San Francisco, California."
How many participants are being allowed in this experiment?
"Yes, you are correct. The clinical trial was originally posted on 3/7/2018 and was last updated on 11/15/2022. The study is enrolling 600 patients across 77 sites."
Will this research be able to accommodate patients that are over 35 years old?
"The age range for eligible patients in this study is between 18 and 75 years old."
What are the main health concerns that Ozanimod has been shown to improve?
"Ozanimod is a medication that can help patients suffering from sclerosis, multiple sclerosis, and carcinoma in situ."
Are we still enrolling participants for this research project?
"The trial is still ongoing and recruiting patients, according to the information provided on clinicaltrials.gov. The listing for the study was first posted on March 7th, 2018 with the most recent update being from November 15th, 2020."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How responsive is this trial?
Typically responds via
Most responsive sites:
- PMG Research of Winston-Salem LLC: < 48 hours
Average response time
- < 2 Days